Ludwig Enterprises, Inc. is an early stage genomic technology company focused on developing screening tests for inflammation related chronic diseases, including cancers. The company utilizes messenger RNA biomarkers, proprietary machine learning algorithms, and at home cheek swab collection kits to enable early detection of disease and support personalized treatment decisions.

Ludwig Enterprises, Inc. expects to generate revenue primarily through the commercialization of its Laboratory Developed Tests, starting with the Revealia™ Breast test. Revenue will come from the sale of at home collection kits and laboratory analysis services performed in CLIA certified labs, as well as licensing of its proprietary algorithms to partner laboratories. The company aims to serve patients through healthcare provider and employer channels under a business to business to consumer model, with payments made either out of pocket or via insurance reimbursement once coverage is secured.

Ludwig Enterprises, Inc. positions itself as an early stage player in the cancer diagnostics market, differentiating itself through its use of messenger RNA biomarkers that reflect active disease processes rather than static DNA based tests. The company claims to be the first to employ a non invasive cheek swab method for collecting mRNA in sufficient quantity for analysis. It faces competition from established firms such as Natera, Guardant Health, Exact Sciences, GRAIL and Freenome, which offer DNA based or multi omics tests. Ludwig's advantages include its proprietary 48 gene inflammatory biomarker panel, machine learning algorithms, and pending patent families covering multiple cancer types. However, many rivals have greater financial resources, established laboratory infrastructure and broader reimbursement networks.

Ludwig Enterprises, Inc. serves patients who obtain testing through healthcare providers, employer and insurer sponsored programs and clinical laboratories. The company has an existing agreement with the CLIA certified laboratory GIA to process samples. It intends to expand its network to include additional independent labs that can offer the test as a laboratory developed test. No other specific customer names are disclosed in the filing.